Anti‐<scp>MDA5</scp> positivity: describing the frequency and spectrum of clinically evident <scp>MDA5</scp> disease
To evaluate experience in a tertiary rheumatology service with melanoma differentiation-association-protein-5 (MDA5) disease and testing, patients with positive autoantibody results were reviewed for the presence of clinical disease. Anti-MDA5 positivity was detected in 2% of myositis-specific antibody tests. Of these, 29% did not have features consistent with anti-MDA5 disease. However, when present, MDA5 disease is severe with a high mortality.
Authors
- Jessica L. Fairley (ORCID: https://orcid.org/0000-0003-4140-2711)
- Eric Francis Morand (ORCID: https://orcid.org/0000-0002-9507-3338)
- Ai Li Yeo (ORCID: https://orcid.org/0000-0001-6242-1562)
- Samar Ojaimi (ORCID: https://orcid.org/0000-0003-2129-1866)
- J. Sée (ORCID: https://orcid.org/0000-0003-1451-2309)
Institutions
- The University of Melbourne (AU)
- Monash Health (AU)
- Monash University (AU)
Publication Details
- Journal
- Internal Medicine Journal
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1111/imj.16563
- Citations
- 1
- Primary Topic
- Adenosine and Purinergic Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.40